ADMA Biologics entered into a $125 million accelerated share repurchase (ASR) agreement with JPMorgan Chase Bank, National Association on March 2, 2026. This ASR is part of the company's previously announced $500 million share repurchase program, disclosed on May 7, 2025. The company will fund the ASR with borrowings from its existing $225 million revolving credit facility with JPMorgan Chase Bank, N.A. ADMA will initially receive approximately 6.4 million shares on or about March 3, 2026, representing about 80% of the shares expected to be repurchased under the ASR. The initial share delivery is based on a closing price of $15.57 per share on February 27, 2026. The total number of shares repurchased will be based on the average daily volume-weighted average price during the ASR term, less an agreed discount, and is expected to be completed within five months. The company targets a total capital return initiative of approximately $200 million during 2026, including this ASR. Since the program's authorization in May 2025, ADMA has repurchased approximately $160 million of its common stock, including this ASR.